Angelini Pharma Buys Catalyst for $4.1B in Rare Disease Push

In a significant move to establish a robust presence in the United States pharmaceutical sector, Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for approximately $4.1 billion in an all-cash transaction. This strategic acquisition immediately propels Angelini Pharma into the U.S. market and substantially bolsters its capabilities in the critical area of neurological rare diseases and brain health.

The deal, unanimously approved by the boards of directors of both companies, values Catalyst Pharmaceuticals at $31.50 per share. This represents a notable premium, reflecting a 21% increase over Catalyst's closing share price prior to market speculation and a 28% uplift compared to its 30-day average trading price. The transaction is anticipated to finalize in the third quarter of 2026, contingent upon shareholder consent and regulatory approvals.

Catalyst Pharmaceuticals brings a valuable portfolio of commercial-stage treatments targeting rare neuromuscular and neurological conditions. Key assets include FIRDAPSE for Lambert-Eaton myasthenic syndrome, AGAMREE for Duchenne muscular dystrophy, and FYCOMPA, used to manage epilepsy-related seizures. This specialized focus aligns perfectly with Angelini Pharma's strategic ambition to deepen its expertise in central nervous system disorders, a therapeutic area experiencing growing unmet medical needs.

Following the integration, Angelini Pharma intends to merge Catalyst's commercial infrastructure and rare disease product line with its existing central nervous system and brain health operations. This synergy aims to forge a formidable global rare disease platform, leveraging the combined strengths of both organizations. The acquisition is supported by a financing package that includes cash and debt facilities, with BNP Paribas serving as the Sole Global Coordinator and Underwriter. Additionally, Blackstone funds and other international partners are contributing to the transaction's funding.

This development coincides with Catalyst Pharmaceuticals announcing a confidential settlement to resolve ongoing U.S. patent litigation concerning FIRDAPSE and a generic competitor, Hetero USA. This resolution removes a significant overhang and positions the acquired assets for continued commercial success under Angelini Pharma's stewardship. The broader rare disease market, particularly for neurological conditions, continues to attract substantial investment due to its high unmet need and potential for significant patient impact.

Sergio Marullo di Condojanni, CEO of Angelini Pharma, highlighted the company's five-year transformation journey, emphasizing the strategic pivot towards CNS disorders and the ambition to compete at a global level. He stated, "Entering the U.S. market will allow us to acquire the scale and capabilities needed to continue this journey." Similarly, Rich Daly, President and CEO of Catalyst Pharmaceuticals, described the acquisition as a "pivotal and transformative moment," underscoring the potential to create a stronger, scalable rare disease platform and enhance patient access to vital therapies.

The acquisition underscores a trend of consolidation within the pharmaceutical industry, particularly among companies focused on niche therapeutic areas like rare diseases. Such deals allow larger entities to rapidly expand their portfolios and market reach while providing significant returns for target company shareholders. Angelini Pharma's move signals a clear intent to become a major player in the U.S. rare disease arena.